期刊名称：CLINICAL AND TRANSLATIONAL MEDICINE ISSN： 2001-1326 出版频率： Continuous publication 出版社： JOHN WILEY & SONS LTD, THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ   出版社网址： https://onlinelibrary.wiley.com/ 期刊网址： https://onlinelibrary.wiley.com/journal/20011326 影响因子： 11.492 主题范畴： ONCOLOGY;    MEDICINE, RESEARCH & EXPERIMENTAL 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aim and Scope Clinical and Translational Medicine (CTM) is an international, peer-reviewed, and open access journal with aims at promoting and accelerating the translation of preclinical research to a clinical application and the communication between basic and clinical scientists. The journal emphasizes clinical potential and application of new biotechnologies, biomaterials, bioengineering, disease-specific biomarkers, cellular and molecular medicine, omics science, bioinformatics, applied immunology, molecular imaging, drug discovery and development, and regulation and health policy. The journal is focused on the bench to bedside approach, favoring studies and clinical observations which generate hypotheses and questions relevant to the patient and disease, and guide the investigations of cellular and molecular medicine. Clinical and Translational Medicine welcomes submissions from clinicians, researchers, policy makers, and the industry. The journal covers all areas of clinical and translational medicine (CTM) but specializes in several Themed Topics: Education and Career Development CTM is a major platform to exchange the knowledge and experience of clinical and translational science to increase awareness and understanding of CTM about the innovation, development, and regulation through dissemination of educational and training resources, including Graduate Communication, Educational Experience, and Talent Introduction. Clinical Studies of Drugs and Devices CTM offers the priority to publish results of interventional and observational studies on responses of human participants to interventions, especially evidence-based data of the improvement, efficacy, safety, toxicity, and outcomes in participants during clinical trials. CTM highly encourages clinical trials of new interventions, e.g. drugs, devices, procedures, or changes to participants' behaviors. Target-Based Drug Discovery and Development Target-based drug discovery and development is a major part of CTM, including target-based screening and identification, validation of target disease-specificity and drugability, computational signs and biosynthesis, drug-specific biomarkers to monitor the efficacy, drug metabolism and pharmacokinetics, target drug optimization and translation into clinical therapy. One of the focuses is protein targets, including enzyme targets, cell-signaling receptors, structural proteins and regulatory factors. Clinical Bioinformatics This topic devotes to articles on the application of clinical informatics, bioinformatics, medical informatics, information technology, mathematics, and omics science and clinical studies on evidence-based approaches in bioinformatics and computational medicine, including data integration and platform, methodologies, tools, big data management, and models for acquiring, storing, organizing and analyzing biomedical data to deliver diagnosis and therapy. Clinical Trans-omics Clinical trans-omics is a new emerging area to integrate clinical phenomes with molecular multi-omics (e.g. genomics/proteomics/metabolomics/transcriptomics), in order to further understand molecular mechanisms of disease, patient sensitivity to therapy, and therapy design and development. This topic addresses the biomedical nature of trans-omic networks and across-points among multi-omic layers and the intrinsic connection of multi-omic profiles. Single-cell Biomedicine This topic is to bring single-cell transcriptomes, DNA sequencing, proteomic profiles, and images into clinical practice, to describe extensive heterogeneity among cells, phenotypes, spatial contexts, and cell sensitivity to therapy, to define new biological and functional categories of cells, and to provide new insights for understanding the pathogenesis and assisting precision decision for therapy. Stem Cell Biology and Therapy This topic highlights experimental and clinical results of stem cell isolation and expansion from adult tissues, umbilical cord blood, umbilical cord and placenta, explores their biological function and therapies. It aims to find out mechanisms that regulate stem cell pluripotency and proliferation, trafficking into peripheral blood, and homing to the damaged tissues. It deals with paracrine- and extracellular microvesicles-mediated effects of stem cell therapies, clinical ethics, regulations, trials, protocols, and practices of stem cell therapies in regenerative medicine. Clinical Genomics This topic covers clinical and translational science of genetic and genomic research on the area of clinical potentials and applications of genomic technology, genome structure and function, genetic modification, databases, bioinformatics, clinical phenotypes and genotypes, biomarkers, precision medicine, disease genomics, pharmagenomics, comparative genomics, systems biology, and regulation policy. Vaccines and Immunotherapy This topic discusses identification and validation of vaccines and immunotherapy for infection and cancer, and defines influencing factors like microenvironment, neoantigens burden, immunoresistant phenotypes, and autoimmune toxicities. It addresses clinical efficacy and safety profile of vaccines and immunotherapy, effects of specific immune cell subsets, cancer neoantigens, and improvement of immune cells–driven anticancer immunity. It is focused on molecular, immunological, and clinical determinants of vaccines and combinatorial immunotherapy regimens. Chronic Metabolic Diseases This topic headlines the importance of chronic metabolic disease, including obesity, diabetes, chronic cardiovascular, pulmonary, and gastroenterological diseases, liver diseases, and cancer. It investigates alterations of genomics, metabolomics, proteomics, peptidomics, glycomics, and lipidomics to explore molecular mechanisms of chronic metabolic diseases, identify disease-specific biomarkers ad therapeutic targets, and develop new therapy strategies. Indexing Embase (Elsevier) PubMed via PMC deposit (NLM) Science Citation Index Expanded (Clarivate Analytics) Web of Science (Clarivate Analytics)   Instructions to Authors 1. Submission  2. Aims and Scope  3. Manuscript Categories and Requirements  4. Preparing the Submission 5. Editorial Policies and Ethical Considerations 6. Author Licensing 7. Publication Process after Acceptance 8. Post Publication 9. Editorial Office Contact Details   Editorial Board Editor-in-Chief     Xiangdong Wang, Fudan University, Shanghai, China Xiangdong Wang, MD, PhD, is a Distinguished Professor of Medicine at Fudan University, Director of Shanghai Institute of Clinical Bioinformatics, and Executive Director of Zhongshan Hospital Institute of Clinical Science, Fudan University. He serves as the President of Chinese Society of Gene Technology, Deputy President of National Committee of Clinical Precision Medicine, Chinese Medical Doctor Association. His main research is focused on single cell sequencing, clinical bioinformatics, disease-specific biomarkers, lung chronic diseases, cancer immunology, and molecular & cellular therapies. He is the author of more than 300 scientific publications with the impact factor about 1100, citation number about 9923, h-index 51, and i10-index 256. Advisory Board   Ambroise Wonkam, University of Cape Town, South Africa   Anna Baranova, George Mason University, USA   Anne Chang AM, Menzies School of Health Research, Australia   Anthony P Salvatore, University of Louisiana-Lafayette, USA   Bill Rhodes, Third Day Advisors LLC, USA   Brett Hambly, University of Sydney, Australia   Charles Powell, Mount Sinai-National Jewish Health Respiratory Institute, USA   Claudio Spada, University of Milan, Italy   Dalin Tang, Worcester Polytechnic Institute, USA   David Ingbar, Harvard Medical School, USA   Francesco Marincola, Refugebiotech, USA   Giuseppe A Marraro, The Second Affiliated Hospital of Fujian Medical University, China   Hong-Wen Deng, Tulane University, USA   Hongyang Wang, Eastern Hepatobiliary Surgery Hospital, National Centre for Liver Cancer, China   Je-Yoel Cho, Seoul National University, Korea   Jie Tian, Chinese Academy of Sciences, China   Judith Gault, University of Colorado, USA   Ju Han Kim, Seoul National University College of Medicine, Korea   Julio Licinio, Flinders University, Australia   Kenneth B. Adler, North Carolina State University, USA   Laszlo Nagy, Johns Hopkins University School of Medicine, USA   Lennart Hammarström, Klin Immunologi o Transfusionsmedicin, Karolinska Institute, Sweden   Lih Kuo, Texas A&M University Health Science Center, USA   Madhav Bhatia, University of Otago, New Zealand   Margit Burmeister, University of Michigan, USA   Marek Malecki, Caribbean Medical University, USA   Mariusz Z. Ratajczak, University of Louisville, USA   Michael Dean, NCI Advanced Technology Research Facility, NIH, USA   Michael Liebman, IPQ Analytics, LLC, USA   Moien Kanaan, Bethlehem University, USA   Nausherwan K Burki, John Dempsey Hospital, USA   Peter L. Elkin, State University of New York, USA   Prabha Sampath, Agency for Science, Technology and Research (A*STAR), Singapore   Sandra Harris-Hooker, Morehouse School of Medicine, USA   Sébastien Sart, Université catholique de Louvain, France   Shi-Jie Chen, University of Missouri-Columbia, USA   Tamir Tuller, Tel Aviv University, Israel   Trushil Shah, UT Southwestern Medical Center, USA   Wei Wang, Edith Cowan University (ECU), Australia   William Cho, Institute of Biomedical Science (UK), China   Yong Hou, Beijing Genome Institute (BGI), China   Yong-Xiao Wang, Albany Medical College, USA   Yoshinori Marunaka, Ritsumeikan University, Japan   Yunfeng Cheng, Fudan University Shanghai Medical College, China   Yuquan Wei, West China Hospital, Sichuan University, China   Zhijun Duan, University of Washington, USA   Zhinan Chen, Fourth Military Medical University, China Publisher Tina Wang, Wiley  Tina Wang received her Ph.D. degree in Biochemistry and Molecular Biology from Institute of Basic Medical Sciences, Peking Union Medical College in 2001 and finished her postdoctoral training in Department of Developmental Neurobiology, St. Jude Children’s Research Hospital in Memphis, Tennessee, United States before joining Wiley in 2011. At present, she is Journal Manager managing a portfolio of scientific journals in the subject areas of Life Sciences and Biomedical Sciences. Her responsibility also includes launching new open access journals in partnership with Chinese institutions. Publishing Assistant Melody Zhang, Wiley  Melody Zhang received her B.A. from Renmin University of China (RUC) and M.A. from The Chinese University of Hong Kong (CUHK). Before joining Wiley, she worked in the Academic Planning and Research Office at RUC School of Business and education start-up. At present, she is supporting journal publishing managers with the management of a portfolio of scientific journals, including new open access journals.